Last updated: September 1, 2026
Atogepant, marketed as Qulipta in the United States and Aquipta in Europe, is AbbVie’s oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention. Its commercial profile has strengthened since the FDA expanded the label from episodic migraine to chronic migraine in 2023. AbbVie reported approximately $1.4 billion in global Qulipta/Aquipta revenue in 2024, up from about $0.8 billion in 2023 and $0.3 billion in 2022.[1]
The product’s growth is driven by three factors: expansion into chronic migraine, increased use of oral preventive therapy, and AbbVie’s scale in neurology and specialty pharmacy distribution. The principal risks are competition from rimegepant, ubrogepant, injectable CGRP antibodies, Botox in chronic migraine, payer controls, and eventual generic entry after regulatory and patent protection expires.
What is atogepant and how is it used?
Atogepant is an oral, small-molecule CGRP receptor antagonist approved for the preventive treatment of migraine in adults. It is not approved for acute treatment of migraine attacks.
| Product |
Market |
Approved use |
Typical strength |
| Qulipta |
United States |
Preventive treatment of episodic and chronic migraine |
10 mg, 30 mg, 60 mg once daily |
| Aquipta |
European Union and selected markets |
Migraine prevention, including chronic migraine where authorized |
Generally 10 mg, 30 mg, 60 mg once daily |
The FDA initially approved Qulipta on September 28, 2021, for preventive treatment of episodic migraine in adults.[2] The FDA approved the chronic migraine indication in 2023, materially expanding the addressable market.[3]
Atogepant’s main commercial advantage is oral once-daily administration. Competing preventive CGRP products include injectable erenumab, fremanezumab, galcanezumab, and eptinezumab. Oral competitors include rimegepant, sold as Nurtec ODT by Pfizer, and ubrogepant, sold as Ubrelvy by AbbVie. Unlike atogepant, rimegepant and ubrogepant are approved for both migraine prevention and acute treatment, giving them broader use across the migraine treatment pathway.
How large is the atogepant market opportunity?
The migraine-prevention market is large but underpenetrated. Migraine affects more than 1 billion people globally, while many patients do not receive preventive therapy despite frequent or disabling attacks.[4] The commercially relevant market is narrower and consists primarily of patients with frequent episodic migraine, chronic migraine, inadequate response to acute therapy, or intolerance to older preventive drugs.
The chronic migraine expansion increased atogepant’s market opportunity because chronic migraine patients often require sustained preventive treatment and have historically been treated with Botox, CGRP antibodies, topiramate, beta blockers, or other off-label therapies.
Addressable patient segments
Atogepant competes across several segments:
- Adults with frequent episodic migraine.
- Adults with chronic migraine.
- Patients who prefer an oral medicine over injections.
- Patients who discontinue older preventive medicines because of cognitive, cardiovascular, weight, or tolerability concerns.
- Patients switching from injectable CGRP antibodies because of administration burden, access restrictions, or inadequate response.
- Patients requiring a preventive option that can be prescribed through primary-care, neurology, or telehealth channels.
The product’s commercial ceiling depends less on the total number of migraine patients than on payer access and the rate at which neurologists move patients from inexpensive generic preventives to branded CGRP therapies.
What is the financial trajectory for Qulipta and Aquipta?
AbbVie’s reported revenue trajectory shows rapid uptake after the 2021 launch and further acceleration after the chronic migraine approval.
| Year |
Reported global revenue |
Approximate year-over-year growth |
Commercial development |
| 2022 |
About $0.3 billion |
Not comparable to launch year |
Early U.S. launch and formulary expansion |
| 2023 |
About $0.8 billion |
More than 150% |
Chronic migraine approval and broader uptake |
| 2024 |
About $1.4 billion |
About 65% |
Continued U.S. growth and international rollout |
Sources: AbbVie annual reporting and earnings disclosures.[1,5]
The 2024 result places Qulipta/Aquipta among AbbVie’s larger growth products. Revenue remains smaller than the company’s leading immunology and oncology franchises, but its growth rate is substantially higher than that of mature products.
What is driving revenue growth?
The main growth drivers are:
- Label expansion. Chronic migraine adds patients who were not covered by the original episodic-migraine indication.
- Oral administration. Some patients prefer a daily tablet to monthly or quarterly injections.
- Commercial infrastructure. AbbVie inherited a large specialty-pharmaceutical sales, reimbursement, and patient-support platform through its Allergan acquisition.
- CGRP class adoption. Physician familiarity with CGRP biology and branded migraine prevention continues to increase.
- Treatment switching. Patients can move from older preventive drugs, Botox, or injectable CGRP antibodies to an oral product.
What could slow the financial trajectory?
Revenue growth may moderate as the product reaches a larger base of treated patients. Principal pressures include:
- Prior authorization and step-therapy requirements.
- Rebates negotiated with pharmacy benefit managers.
- Competition from Nurtec ODT and established CGRP antibodies.
- Use of low-cost generic topiramate, propranolol, or valproate before branded products.
- Patient discontinuation caused by side effects, adherence challenges, or limited perceived benefit.
- Generic competition after loss of regulatory and patent protection.
- Cannibalization within AbbVie’s migraine portfolio, particularly between Qulipta and Ubrelvy.
AbbVie does not generally disclose profit margins for Qulipta separately. The product likely has favorable incremental economics because it is an orally administered small molecule and uses AbbVie’s existing commercial infrastructure. Net pricing, rebates, patient assistance, and international reference pricing will determine realized margin.
How does atogepant compare with Nurtec and Ubrelvy?
Atogepant’s competitive position depends on whether the physician is choosing a preventive-only therapy or a product with both acute and preventive utility.
| Attribute |
Atogepant |
Rimegepant |
Ubrogepant |
| Brand |
Qulipta/Aquipta |
Nurtec ODT |
Ubrelvy |
| Company |
AbbVie |
Pfizer |
AbbVie |
| Oral administration |
Once daily for prevention |
Orally disintegrating tablet |
As-needed tablet |
| Preventive use |
Yes |
Yes |
No |
| Acute treatment |
No |
Yes |
Yes |
| Chronic migraine approval |
Yes in the U.S. |
Prevention indication is narrower than atogepant’s chronic-migraine label as of mid-2024 |
No |
| Core commercial position |
Dedicated oral preventive |
Dual-use acute and preventive product |
Acute migraine treatment |
Atogepant has an advantage in chronic migraine prevention and a simple once-daily regimen. Rimegepant has a broader acute-plus-preventive value proposition and a differentiated orally disintegrating formulation. Ubrelvy is an acute-treatment product and is not a direct substitute for atogepant in prevention, although AbbVie can sell both products to the same prescriber base.
What FDA regulatory status protects atogepant?
The FDA approved Qulipta as a new molecular entity for migraine prevention on September 28, 2021.[2] The chronic migraine supplemental approval expanded the labeled patient population in 2023.[3]
| Regulatory item |
Status |
| FDA approval |
Approved |
| Initial indication |
Preventive treatment of episodic migraine |
| Expanded indication |
Preventive treatment of chronic migraine |
| Dosage forms |
Immediate-release oral tablets |
| Controlled substance status |
Not a controlled substance |
| Biosimilar pathway |
Not applicable |
| ANDA generic pathway |
Applicable after patent and regulatory barriers permit |
Atogepant is a small molecule, so future competition will come through abbreviated new drug applications rather than biosimilar applications. FDA approval of a generic will still depend on the status of listed patents, regulatory exclusivity, settlement terms, and any litigation.
When does atogepant lose exclusivity?
Atogepant’s five-year new chemical entity exclusivity began with the September 28, 2021, FDA approval and generally runs through September 28, 2026.[2] During this period, the FDA cannot accept an ANDA that relies on the product’s approval, subject to statutory exceptions.
NCE exclusivity is separate from patent protection. Patent rights may block generic launch beyond 2026, while patents can also expire before or after the regulatory exclusivity period.
Atogepant exclusivity timeline
| Date |
Event |
| September 28, 2021 |
FDA approval of Qulipta for episodic migraine prevention |
| September 28, 2026 |
Expected end of five-year NCE exclusivity, absent an applicable extension |
| 2026 onward |
Potential ANDA activity, subject to listed patents and litigation |
| Post-2026 |
Generic entry timing depends on Paragraph IV certifications, settlements, and court outcomes |
The chronic migraine indication does not create a new five-year NCE exclusivity period because it is an expanded indication for the same active ingredient. It may support separate method-of-use patent protection, but that protection does not necessarily block all generic versions.
What patents protect atogepant?
Atogepant is protected by a combination of composition-of-matter, pharmaceutical composition, formulation, and method-of-use rights. The relevant patent estate is associated with AbbVie and entities acquired through Allergan.
The Orange Book is the controlling source for patents listed against the approved Qulipta product. Patent scope and expiry should be assessed separately for:
- Atogepant as an active pharmaceutical ingredient.
- Specific tablet formulations.
- Dose regimens.
- Use in chronic migraine prevention.
- Use in episodic migraine prevention.
- Manufacturing and process technologies.
Composition-of-matter protection is typically the most commercially important because it can cover the active ingredient across multiple indications and formulations. Method-of-use patents are narrower because a generic applicant may attempt to carve out a patented indication from its label.
How strong is the patent estate?
The estate is commercially meaningful because atogepant is a prescription small molecule with multiple potential claim categories. Its practical strength depends on:
- Whether the core composition claims remain valid and enforceable.
- The expiry dates of the earliest active ingredients and later-issued patents.
- Whether Orange Book-listed patents cover the tablet product or only specific uses.
- The ability of generic applicants to use skinny-label strategies.
- The outcome of any Paragraph IV litigation.
- The extent to which formulation patents cover commercially necessary dosage strengths.
A strong composition patent can delay broad generic entry. Formulation and method-of-use patents are more vulnerable to design-around strategies and indication carve-outs.
Are there Paragraph IV challenges or generic lawsuits against Qulipta?
Publicly available information through mid-2024 did not show a major reported Paragraph IV litigation campaign against Qulipta comparable to the litigation surrounding older blockbuster drugs. The absence of reported litigation at that point does not eliminate future challenge risk.
Generic applicants could file Paragraph IV certifications after the relevant regulatory restrictions lapse. Potential challenge targets would include Orange Book-listed patents covering:
- Atogepant tablets.
- Specific dosage strengths.
- Chronic migraine prevention.
- Episodic migraine prevention.
- Pharmaceutical compositions.
A Paragraph IV filing could trigger a 45-day period for the patent holder to sue and, if litigation is timely filed, an automatic stay of FDA approval for up to 30 months under the Hatch-Waxman framework.[6]
What patent litigation and settlement risks affect atogepant?
The principal future litigation risk is a Hatch-Waxman challenge by an ANDA applicant. The likely dispute areas are patent validity, obviousness, written description, enablement, infringement, and the scope of method-of-use claims.
Potential settlement outcomes include:
- Generic launch on an agreed date before patent expiry.
- A license with a date certain.
- A launch tied to the invalidation or expiration of selected patents.
- No-revenue-sharing or limited-revenue-sharing arrangements.
- Restrictions on the generic label for patented indications.
A settlement that permits entry before the latest asserted patent expiry could reduce the value of Qulipta’s long-tail revenue. A settlement that preserves a late launch could extend the branded revenue curve but may face antitrust scrutiny.
What licensing deals and ownership history affect atogepant?
AbbVie obtained atogepant through its acquisition of Allergan, which closed in 2020.[7] Atogepant was part of Allergan’s migraine portfolio alongside Botox and other neurology assets.
The ownership history matters commercially because AbbVie can coordinate:
- Qulipta for prevention.
- Ubrelvy for acute treatment.
- Botox for chronic migraine.
- Existing neurologist and specialty-pharmacy relationships.
- Patient-support and reimbursement programs.
No separate external licensing transaction is required to explain the current commercial ownership structure. AbbVie is the principal global pharmaceutical company responsible for the Qulipta/Aquipta franchise.
What is the international market status of Aquipta?
The European Commission authorized Aquipta in 2023 for migraine prevention in adults with at least four migraine days per month, subject to the approved product information and national reimbursement decisions.[8]
International expansion creates additional revenue but also introduces:
- National health technology assessment requirements.
- Price controls and external reference pricing.
- Slower reimbursement adoption than in the United States.
- Local patent and supplementary protection certificate analysis.
- Parallel trade risk in Europe.
- Country-specific restrictions on chronic migraine use.
The United States remains the central profit pool because branded prescription pricing is generally higher and AbbVie controls a large commercial infrastructure. Europe and other markets can extend volume growth but usually contribute lower net revenue per treated patient.
What generic entry risks exist for atogepant?
Generic entry risk is limited before the end of NCE exclusivity in 2026, then increases in stages.
Early generic scenario
A generic applicant files an ANDA with Paragraph IV certifications shortly after the regulatory barrier ends. AbbVie sues within the statutory period. FDA approval may be stayed for up to 30 months, creating a potential launch around 2029 unless the case resolves earlier.
Midpoint scenario
AbbVie reaches a settlement allowing generic entry before the latest patent expiry. Revenue declines gradually as one or more authorized or independent generics enter.
Late-entry scenario
Core composition and formulation patents survive litigation, and generic launch is delayed until the late 2020s or early 2030s. Qulipta retains substantial revenue but faces price erosion from competing branded CGRP therapies.
Commercial erosion after generic launch
Oral small-molecule migraine products can experience rapid prescription switching once multiple generics receive approval. The speed of erosion will depend on:
- Number of approved ANDAs.
- Formulary substitution.
- Generic discounts.
- Whether AbbVie launches an authorized generic.
- Persistence of chronic migraine patients on branded therapy.
- Continued protection for selected indications or strengths.
How does atogepant compare with injectable CGRP antibodies and Botox?
Atogepant’s main differentiation is administration and reversibility. A patient can stop a daily tablet without waiting for a long-acting injection to clear. Injectable antibodies offer monthly or quarterly dosing and may support adherence for patients who prefer infrequent administration.
Botox remains a major chronic migraine competitor because it has an established physician-administered pathway and long clinical experience. Atogepant can compete as an oral alternative, but payers may require prior failure of older therapies, CGRP antibodies, or Botox depending on the plan.
| Competitive class |
Commercial strength |
Limitation versus atogepant |
| CGRP monoclonal antibodies |
Infrequent dosing and established prevention use |
Injection or infusion requirement |
| Botox |
Established chronic migraine use |
Procedure-based administration |
| Topiramate and other generics |
Low cost |
Tolerability and adherence concerns |
| Rimegepant |
Acute and preventive utility |
Different dosing and formulation profile |
| Ubrogepant |
Strong acute-treatment position |
Not approved for prevention |
What is the investment outlook for atogepant?
Atogepant is a high-growth asset within AbbVie’s post-Humira diversification strategy. The revenue trajectory supports a multibillion-dollar cumulative opportunity if chronic migraine penetration increases and international reimbursement expands.
The investment case is strongest through the late 2020s because:
- The product has a differentiated oral preventive position.
- The chronic migraine label expands the market.
- CGRP use is still moving from specialist adoption toward broader prescribing.
- AbbVie can cross-sell across its migraine portfolio.
- Generic competition is unlikely to materially affect revenue before the regulatory exclusivity period ends.
The principal valuation risk is overestimating durability after 2026. Long-term revenue depends on the actual patent estate, Paragraph IV outcomes, settlement timing, payer rebate pressure, and competition from dual-use products such as rimegepant.
Key Takeaways
- Atogepant is AbbVie’s oral CGRP antagonist for migraine prevention, sold as Qulipta in the U.S. and Aquipta internationally.
- FDA approval began in September 2021 for episodic migraine; chronic migraine approval followed in 2023.
- Global revenue increased from about $0.3 billion in 2022 to about $0.8 billion in 2023 and approximately $1.4 billion in 2024.
- Five-year NCE exclusivity is expected to run through September 2026.
- Future generic entry will depend on Orange Book patents, Paragraph IV challenges, litigation stays, and settlement agreements.
- The principal competitors are rimegepant, ubrogepant, CGRP antibodies, Botox, and low-cost generic preventives.
- AbbVie’s ownership of both Qulipta and Ubrelvy creates portfolio advantages but also potential internal substitution.
- Chronic migraine expansion is the most important regulatory and commercial catalyst.
- The strongest long-term protection would come from valid composition-of-matter and product patents; method-of-use patents may be more vulnerable to label carve-outs.
- Atogepant has a favorable near-term growth outlook, but revenue durability after 2026 is the central patent and market-access question.
FAQs about atogepant market dynamics
What is the peak-sales potential for atogepant?
Atogepant has a credible multibillion-dollar cumulative opportunity, but peak annual sales depend on U.S. payer access, chronic migraine penetration, international reimbursement, and generic timing. Its 2024 global revenue of roughly $1.4 billion indicates that the product has moved beyond an early-launch asset.
Does AbbVie’s Qulipta compete with its own Ubrelvy product?
Yes. Both products target the CGRP pathway and can be prescribed to overlapping migraine patients. Qulipta is positioned for prevention, while Ubrelvy is positioned for acute treatment. The portfolio also allows AbbVie to retain patients across different stages of migraine therapy.
Is atogepant a biologic drug?
No. Atogepant is an orally administered small molecule. Future competitors will seek FDA approval through the ANDA generic-drug pathway rather than the biosimilar pathway.
Can a generic atogepant product be approved for only episodic migraine?
Potentially. A generic applicant may seek a label that omits a patented indication if FDA labeling and patent requirements permit a lawful skinny-label strategy. The commercial effect would depend on the scope of the remaining patents and prescribing practices.
Why is chronic migraine important to Qulipta revenue?
Chronic migraine patients generally have a greater need for preventive therapy and may use treatment over longer periods. The 2023 label expansion materially increased the number of eligible U.S. patients and strengthened Qulipta’s position against Botox and injectable CGRP antibodies.
References
- AbbVie Inc. (2025). 2024 annual report. AbbVie.
- U.S. Food and Drug Administration. (2021, September 28). FDA approves new treatment for adults with migraine. FDA.
- U.S. Food and Drug Administration. (2023). Qulipta prescribing information. FDA.
- GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019. The Lancet, 396(10258), 1204-1222.
- AbbVie Inc. (2024). 2023 annual report. AbbVie.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
- AbbVie Inc. (2020). AbbVie completes acquisition of Allergan. AbbVie.
- European Medicines Agency. (2023). Aquipta: EPAR - product information. EMA.
